NSAIDs also have harmful effects on the liver, kidneys, GI tract and cardiovascular system, while steroids can affect blood sugar levels and cause weight gain, exacerbating metabolic issues that contribute to knee OA
This article aims to provide an overview of GLP-1 based drugs, focusing on semaglutide (marketed as Ozempic for type 2 diabetes and as Wegovy for obesity) and tirzepatide (marketed as Mounjaro), which is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 agonist
Mice with AhR deficiency in microglia, a macrophage population in the brain, develop more severe EAE, with increased expression of pro-inflammatory genes and loss of IL-10 and transforming growth factor- (TGF-) expression
Human APOE isoforms differentially modulate brain glucose and ketone body metabolism: implications for Alzheimer's disease risk reduction and early intervention
Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A, Milicevic Z, Coskun T
Wegovy and Zepbound are FDA-approved for weight loss, which can make them *easier* to get covered than Ozempic, but its still not guaranteed